Latest investigations into retatrutide peptide reveal promising possibility for treating excess body and type diabetes. The compound, a dual agonist of glucagon-like peptide-1 and GIP receptor, looks to offer enhanced weight loss and glucose regulation versus existing therapies. Ongoing patient s